Abstracts Archive - Page 1392 of 2425 - ACR Meeting Abstracts

Abstract Number: 2797 • 2017 ACR/ARHP Annual Meeting
Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study
Arthur Kavanaugh¹, Yannick Allanore², Eugeniusz J. Kucharz³ and Goran Babic⁴, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Rheumatology, Cochin Hospital, Paris Descartes University, Paris, France, ³Department of Internal Medicine and Rheumatology, Medical University of Silesia, Katowice, Poland, ⁴Clinical development, Biopharmaceuticals, Hexal AG, a Sandoz company, Holzkirchen, Germany
Background/Purpose: The biosimilarity of GP2015 and etanercept originator product (ETN) has been previously demonstrated in patients with chronic plaque-type psoriasis.1 The randomized, double-blind, phase 3…
Abstract Number: 2798 • 2017 ACR/ARHP Annual Meeting
A Randomized, Double-Blind Study Comparing PF-06438179/GP1111, a Potential Infliximab Biosimilar, and Infliximab, Both in Combination with MTX, As Treatment for Patients with Moderate to Severe Active RA Who Have Had an Inadequate Response to MTX Therapy
Stanley B Cohen¹, Rieke Alten², Hideto Kameda³, Muhammad I. Rehman⁴, Karl Schumacher⁵, Susanne Schmitt⁵, Steven Y. Hua⁶ and K. Lea Sewell⁷, ¹Metroplex Clinical Research Center, Dallas, TX, ²Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, ⁴Pfizer Inc, Andover, MA, ⁵Global Clinical Development, Biopharmaceuticals, Hexal AG, Holzkirchen, Germany, ⁶Pfizer Inc, San Diego, CA, ⁷Biosimilars Development, Pfizer Inc, Cambridge, MA
Background/Purpose: This double-blind, randomized study evaluated efficacy, safety and immunogenicity of PF‑06438179/GP1111, a potential infliximab biosimilar, vs infliximab sourced from the EU (infliximab-EU) in patients…
Abstract Number: 2799 • 2017 ACR/ARHP Annual Meeting
Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and Open-Label Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)
Mark C. Genovese¹, Josephine Glover², Nobuhito Matsunaga³, Diane Chisholm⁴ and Rieke Alten⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²Coephycient Pharmaceutical Consultancy, Guildford, United Kingdom, ³Fujifilm Kyowa Kirin Biologics, Chiyoda-ku, Tokyo, Japan, ⁴Fujifilm Kyowa Kirin Biologics, Galashiels, United Kingdom, ⁵University Medicine Berlin, Berlin, Germany
Background/Purpose: FKB327 is a proposed biosimilar of the adalimumab RP. A randomized, DB, Phase 3 study (NCT02260791) compared the efficacy, safety, pharmacokinetics (PK) and immunogenicity…
Abstract Number: 2800 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Biosimilar Infliximab (CT-P13) after Switching from Originator Infliximab: Results from the 26-Week Open Label Extension of a Randomized Norwegian Trial
Guro Løvik Goll¹, Kristin Kaasen Jørgensen², Joe Sexton¹, Inge C Olsen³, Nils Bolstad⁴, Merete Lorentzen⁵, Espen A. Haavardsholm⁶, Cato Mork⁷, Jorgen Jahnsen⁸ and Tore K Kvien⁹, ¹Dept Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ⁵Dept of Dermatology, Rikshospitalet, Oslo, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept of cancer and Molecular medicine, Norwegian University of Science and Technology, Trondheim, Norway, ⁸Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, ⁹Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) , Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
Abstract Number: 2801 • 2017 ACR/ARHP Annual Meeting
Effects of Anti-IL17 Blockade with Secukinumab on Systemic and Local Immune Responses: A Mechanism-of-Action Study in Peripheral Spondyloarthritis
Leonieke van Mens¹, Marleen van de Sande², Silvia Menegatti³, Iris Blijdorp¹, Jet de Jong², Inka Fluri⁴, Talia Latuhihin¹, Arno van Kuijk⁵, Nataliya Yeremenko⁴ and Dominique Baeten¹, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Immunology, Immunoregulation Unit, Institut Pasteur, Paris, France, ⁴Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ⁵Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: IL-17A blockade is an effective therapy for AS and PsA, the prototypical forms of spondyloarthritis(SpA). How IL-17A blockade affects the systemic and local immune…
Abstract Number: 2802 • 2017 ACR/ARHP Annual Meeting
Sustained Remission of Inflammation Is Associated with Reduced Structural Damage on SI Joint MRI in Patients with Early Axial Spa: Evidence to Support the Concept of Treat-to-Target
Walter P. Maksymowych¹, Pascal Claudepierre², Manouk de Hooge³, Robert G. Lambert⁴, Robert B.M. Landewé⁵, Anna Molto⁶, Désirée van der Heijde³, Jack F Bukowski⁷, Heather Jones⁸, Isabelle Logeart⁹, Lisa Marshall⁸, Ronald Pedersen¹⁰, Annette Szumski¹¹, Bonnie Vlahos¹² and Maxime Dougados¹³, ¹Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ²Universite Paris Est Creteil, Paris, France, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ⁵Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁶Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁷Clinical Affairs, Pfizer, Collegeville, PA, ⁸Inflammation & Immunology Global Medical Affairs, Pfizer, Collegeville, PA, ⁹Medical Affairs, Pfizer, France, Paris, France, ¹⁰Department of Biostatistics, Pfizer, Collegeville, PA, ¹¹Biostatistics, inVentiv Health, Princeton, NJ, ¹²Clinical Sciences, Pfizer, Collegeville, PA, ¹³Hopital Cochin, Paris Descartes University, Paris, France
Background/Purpose: Treat-to-target is an accepted strategy in RA; however, it is unknown whether it will reduce/prevent disability, impairment of mobility, and structural damage in patients…
Abstract Number: 2803 • 2017 ACR/ARHP Annual Meeting
Predictors of Remission Maintenance up to Week 68 and Successful Therapy Discontinuation in Patients with Non-Radiographic Axial Spondyloarthritis Who Achieved Sustained Remission on 28-Week Open-Label Adalimumab Treatment
Joachim Sieper¹, Robert B.M. Landewé², Marina N. Magrey³, Jaclyn K. Anderson⁴, Sheng Zhong⁴, Xin Wang⁴ and Apinya Lertratanakul⁴, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²University of Amsterdam, Amsterdam, Netherlands, ³Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Sustained remission is an important treatment goal in patients (pts) with non-radiographic axial SpA (nr-axSpA). Factors predicting successful remission maintenance are unknown. We sought…
Abstract Number: 2804 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Ankylosing Spondylitis: A Nationwide Population Study
Yao-Fan Fang, Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Taoyuan, Taiwan
Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide population study.Background/Purpose: Autoimmune inflammatory diseases influence on pregnancy outcomes. But rare studies have focus on the…
Abstract Number: 2805 • 2017 ACR/ARHP Annual Meeting
Juvenile-Onset Ankylosing Spondylitis Has a Lower Rate of Radiographic Progression Than Adult-Onset Ankylosing Spondylitis
Anthony So¹, Ammepa Anton², Florence Tsui³, Ismail Sari⁴, Renise Ayearst⁵, Robert D Inman⁶ and Nigil Haroon⁴, ¹University of British Columbia, Vancouver, BC, Canada, ²University Health Network, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ⁵Medicine, University Health Network, Toronto, ON, Canada, ⁶Department of Immunology, University of Toronto, Toronto, ON, Canada
Background/Purpose: There are no large radiographic follow up studies assessing progression in juvenile-onset Ankylosing Spondylitis (JoAS) as compared to adult-onset Ankylosing Spondylitis (AoAS). The purpose…
Abstract Number: 2806 • 2017 ACR/ARHP Annual Meeting
Integrated Longitudinal Analysis Increases Precision and Reduces Bias: A Comparative 5-Year Analysis in the DESIR Cohort
Alexandre Sepriano¹, Sofia Ramiro², Désirée van der Heijde¹, Maxime Dougados³, Pascal Claudepierre⁴, Antoine Feydy⁵, M. Reijnierse⁶, Damien Loeuille⁷ and Robert B.M. Landewé⁸, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³Paris-Descartes University,, Paris, France, ⁴Hôpital Henri Mondor, Créteil, France, ⁵Univ. Paris Descartes, PRES Sorbonne Paris Cité, Service de radiologie B, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, Paris, France, ⁶Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology, CHRU Nancy, Vandoeuvre les Nancy, France, ⁸University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands
Background/Purpose: Evaluation of imaging is important in spondyloarthritis (SpA) research, but loss to follow up often jeopardizes interpretation of the evaluation. The Interpretation may further…
Abstract Number: 2807 • 2017 ACR/ARHP Annual Meeting
Can the Automated Neuropsychological Assessment Metrics (ANAM) Predict Cognitive Impairment Compared to a Comprehensive Neuropsychological Battery in Patients with Lupus?
Zahi Touma¹, Dorcas Beaton², Carmela Tartaglia³, Lesley Ruttan⁴, Sabrina Lombardi⁴, Nicole Anderson⁵, Jiandong Su⁶, Kenneth Colosimo⁷, Michelle Vitti⁷, Dennisse Bonilla⁸, Joan E. Wither⁹, Marvin J. Fritzler¹⁰ and Robin Green¹¹, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada, ³University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁴Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁵Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁰Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Brain and Therapeutics, Toronto Rehabilitation Institute, Toronto, ON, Canada
Background/Purpose: Currently, the diagnosis of cognitive impairment (CI) is often delayed requiring use of a comprehensive battery (CB) which imposes a time- and cost-burden. It…
Abstract Number: 2808 • 2017 ACR/ARHP Annual Meeting
Longitudinal Assessment of Cognitive Function in SLE: Identification of Trajectories
Zahi Touma¹, Jiandong Su² and Patricia P. Katz³, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Cognitive function may change over time in patients with SLE, and cognitive function trajectories (CFTs) have not well been studied. This is the first…
Abstract Number: 2809 • 2017 ACR/ARHP Annual Meeting
Spatial Navigation Impairment Associated with Anti-NMDA Receptor Antibodies in Systemic Lupus Erythematosus
Erik Anderson¹, Elisabeth J. Ploran², Betty Diamond³, Bruce Volpe⁴, Cynthia Aranow⁵ and Meggan Mackay^6,7, ¹Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ²Department of Psychology, Hofstra University, Hempstead, NY, ³Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ⁴Biomedical Sciences, The Feinstein Institute for Medical Research, Manhasset, NY, ⁵The Feinstein Institute for Medical Research, Manhasset, NY, ⁶Autoimmune & Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ⁷Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhassett, NY
Background/Purpose: Cognitive impairment is well-documented in SLE with considerable impact on quality of life but attribution is limited by a lack of biomarkers that distinguish…
Abstract Number: 2810 • 2017 ACR/ARHP Annual Meeting
The Impact of Psychiatric Comorbidity on Health Care Utilization for Youth with Systemic Lupus Erythematosus
Andrea M. Knight^1,2, Alaina M. Davis³, Marisa S. Klein-Gitelman⁴, Zuleyha Cidav⁵ and David Mandell⁶, ¹Division of Rheumatology, Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ²Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Division of Pediatric Rheumatology, Nashville, TN, ⁴Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, ⁵Perelman School of Medicine, Center for Mental Health Policy and Services Research, University of Pennsylvania, Philadelphia, PA, ⁶Psychiatry and Pediatrics, Center for Mental Health Policy and Services Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Youth with systemic lupus erythematosus (SLE) have high health care utilization, which may be exacerbated by psychiatric disorders, a common comorbidity in this group.…
Abstract Number: 2811 • 2017 ACR/ARHP Annual Meeting
Economic Evaluation of Damage Accrual in a Nationwide Canadian SLE Cohort
May Choi¹, Yvan St. Pierre², Murray Urowitz³, Dafna D Gladman⁴, Sasha Bernatsky⁵, Evelyne Vinet⁶, Christian Pineau⁷, John G Hanly⁸, Christine A. Peschken⁹, Paul R. Fortin¹⁰, Michelle Jung¹¹, Claire Barber¹², Susan Elliott¹³, Jenna Dixon¹⁴ and Ann E. Clarke¹¹, ¹University of Calgary, Calgary, AB, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Centre for Prongosis Studies in The Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁶Divisions of Rheymatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁷Rheumatology, MUHC, Montreal, QC, Canada, ⁸Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁹RR 149G, Univ of Manitoba, Winnipeg, MB, Canada, ¹⁰Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada, ¹¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹²Medicine, University of Calgary, Calgary, AB, Canada, ¹³GEOGRAPHY AND ENVIRONMENTAL MANAGEMENT, University of Waterloo, Waterloo, ON, Canada, ¹⁴Geography and Environmental Management, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: We describe the costs associated with damage states in a Canadian-wide SLE cohort using multi-state modeling, which provides a dynamic representation of damage accrual…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].